

Patient:
DOB: Age: Gender:
Patient Identifiers:
Visit Number (FIN):


Client:

Physician:

ARUP Test Code: 2012521

Collection Date:
Received in lab:
Completion Date:

	Patient Score (Range 0-1)	Metavir Classification¹
FibroMeter (fibrosis score)	0.94	F3/F4
	Equal probability between F3 and F4	



Patient Blood Marker Results

Marker	Result	Reference Interval	Units
ALT	75	5-40	U/L
AST	75	9-40	U/L
Ferritin	50	18-340	ng/mL
Glucose	200	<=100	mg/dL
Platelets ²	100		k/uL
Weight ²	150		lbs

Interpretive Information

- Calculations for the final report are based on accurate data for age, weight (± 5 pounds) and platelet count. If any of the information needs to be corrected, please contact ARUP Client Services at (800) 242-2787.
- The Echosens FibroMeter NAFLD profile serves as a surrogate marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Results may be inaccurate in patients who were not fasting at blood draw, or with other etiologies or chronic liver diseases, such as viral hepatitis or alcoholic liver disease. A proprietary algorithm calculates results from 5 blood markers along with age and weight to provide a patient score (0-1) and a correlated fibrosis stage (Metavir F0-F4). Patients must be fasting at the time of blood draw. Results should be interpreted in conjunction with the patient's clinical history.
- Results should be interpreted with caution if the patient is: under 18 years of age; pregnant; has acute hepatitis; other cause of chronic liver disease; severe chronic inflammatory disease other than liver disease, such as arthritis, organ failure other than liver, such as kidney; iron deficiency; unstable glucose levels; unstable weight.

¹ Metavir is a histological scoring system for determining the extent of liver fibrosis and inflammation.

STAGE OF FIBROSIS (F scale)
 F0 = no fibrosis
 F1 = portal fibrosis without septa
 F2 = portal fibrosis with few septa
 F3 = numerous septa without cirrhosis
 F4 = cirrhosis

² Values provided by the client.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.



Patient:
ARUP Accession: 21-153-106873